Global Cancer Test

Cancer Test Comprehensive Study by Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), Application (Bladder Cancer Test, Breast Cancer Test, Cervical Cancer Test, Colorectal (Colon) Cancer Test, Ovarian Cancer Test, Prostate Cancer Test, Liver Cancer Test, Flow Cytometry, Other Organ Specific Cancer Test) Players and Region - Global Market Outlook to 2030

Cancer Test Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Cancer Test
Cancer tests are tests that look for the presence of cancer in healthy people or people without symptoms of cancer. Cancer tests are designed to find cancers at an early stage when they are more treatable. Some cancer tests have been found to lower the death rate (mortality rate) from certain cancers. Examples of some common cancer screening tests that are known to lower cancer death rates include colonoscopy for colon cancer, mammography for breast cancer, and Pap smear for cervical cancer. Some cancer screening tests are suggested only for people at high risk of developing cancer, such as MRI of the breast for women at increased risk of breast cancer.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Cancer Test is highly competitive, with several key players dominating the industry. The market players are focused on developing a variety of features and benefits to meet the needs. Thus, constantly introducing new innovation in processing to meet the changing needs and preferences of consumers. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Cancer Test market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Radient Pharmaceuticals (United States), BD Diagnostics (United States), Beckman Coulter (United States), BioCurex (Mongolia), bioMerieux (France), Cepheid (United States), CytoCore (United States) and DiagnoCure (Canada) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Hologic (United States), IIumina Inc. (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Cancer Test market by Type (Laboratory Tests, Genetic Tests, Imaging and Endoscopy), Application (Bladder Cancer Test, Breast Cancer Test, Cervical Cancer Test, Colorectal (Colon) Cancer Test, Ovarian Cancer Test, Prostate Cancer Test, Liver Cancer Test, Flow Cytometry and Other Organ Specific Cancer Test) and Region.



On the basis of geography, the market of Cancer Test has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Growth Drivers:
Increasing Ease of Cancer Diagnosis and Increasing Healthcare Expenditure

Challenges:
High cost of diagnostic imaging.

Restraints:
Limited Use in the Emerging Markets and A High Cost Associated with the Cancer Test

Opportunities:
Technological Advancements in Cancer Test

Market Leaders and their expansionary development strategies
In August 2021, Illumina, the global leader in DNA sequencing, first announced its intention to acquired GRAIL, reuniting Illumina with GRAIL four years after it was spun off. GRAIL's Galleri blood test detects 50 different cancers before they are symptomatic. Illumina's acquisition of GRAIL has accelerated access and adoption of this life-saving test worldwide.
In November 2023, A new Roswell Park Comprehensive Cancer Center innovation has just gone global. Called PanHeme, it’s a test that uses next-generation gene sequencing technology to diagnose blood cancers like leukemia, lymphoma and multiple myeloma more precisely identifying mutations in hundreds of genes in under 72 hours, a dramatic improvement from the three- to four-week wait time for current molecular testing.


Key Target Audience
Cancer Test Key Stakeholders, Cancer Test Equipment’s Manufacturers, Research Institutes, Regulatory Bodies, Government Bodies, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Laboratory Tests
  • Genetic Tests
  • Imaging
  • Endoscopy
By Application
  • Bladder Cancer Test
  • Breast Cancer Test
  • Cervical Cancer Test
  • Colorectal (Colon) Cancer Test
  • Ovarian Cancer Test
  • Prostate Cancer Test
  • Liver Cancer Test
  • Flow Cytometry
  • Other Organ Specific Cancer Test
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Ease of Cancer Diagnosis
      • 3.2.2. Increasing Healthcare Expenditure
    • 3.3. Market Challenges
      • 3.3.1. High cost of diagnostic imaging.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Test, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Cancer Test (Value)
      • 5.2.1. Global Cancer Test by: Type (Value)
        • 5.2.1.1. Laboratory Tests
        • 5.2.1.2. Genetic Tests
        • 5.2.1.3. Imaging
        • 5.2.1.4. Endoscopy
      • 5.2.2. Global Cancer Test by: Application (Value)
        • 5.2.2.1. Bladder Cancer Test
        • 5.2.2.2. Breast Cancer Test
        • 5.2.2.3. Cervical Cancer Test
        • 5.2.2.4. Colorectal (Colon) Cancer Test
        • 5.2.2.5. Ovarian Cancer Test
        • 5.2.2.6. Prostate Cancer Test
        • 5.2.2.7. Liver Cancer Test
        • 5.2.2.8. Flow Cytometry
        • 5.2.2.9. Other Organ Specific Cancer Test
      • 5.2.3. Global Cancer Test Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Cancer Test: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Radient Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BD Diagnostics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Beckman Coulter (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioCurex (Mongolia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioMerieux (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cepheid (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CytoCore (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DiagnoCure (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Cancer Test Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Cancer Test (Value)
      • 7.2.1. Global Cancer Test by: Type (Value)
        • 7.2.1.1. Laboratory Tests
        • 7.2.1.2. Genetic Tests
        • 7.2.1.3. Imaging
        • 7.2.1.4. Endoscopy
      • 7.2.2. Global Cancer Test by: Application (Value)
        • 7.2.2.1. Bladder Cancer Test
        • 7.2.2.2. Breast Cancer Test
        • 7.2.2.3. Cervical Cancer Test
        • 7.2.2.4. Colorectal (Colon) Cancer Test
        • 7.2.2.5. Ovarian Cancer Test
        • 7.2.2.6. Prostate Cancer Test
        • 7.2.2.7. Liver Cancer Test
        • 7.2.2.8. Flow Cytometry
        • 7.2.2.9. Other Organ Specific Cancer Test
      • 7.2.3. Global Cancer Test Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Test: by Type(USD Million)
  • Table 2. Cancer Test Laboratory Tests , by Region USD Million (2018-2023)
  • Table 3. Cancer Test Genetic Tests , by Region USD Million (2018-2023)
  • Table 4. Cancer Test Imaging , by Region USD Million (2018-2023)
  • Table 5. Cancer Test Endoscopy , by Region USD Million (2018-2023)
  • Table 6. Cancer Test: by Application(USD Million)
  • Table 7. Cancer Test Bladder Cancer Test , by Region USD Million (2018-2023)
  • Table 8. Cancer Test Breast Cancer Test , by Region USD Million (2018-2023)
  • Table 9. Cancer Test Cervical Cancer Test , by Region USD Million (2018-2023)
  • Table 10. Cancer Test Colorectal (Colon) Cancer Test , by Region USD Million (2018-2023)
  • Table 11. Cancer Test Ovarian Cancer Test , by Region USD Million (2018-2023)
  • Table 12. Cancer Test Prostate Cancer Test , by Region USD Million (2018-2023)
  • Table 13. Cancer Test Liver Cancer Test , by Region USD Million (2018-2023)
  • Table 14. Cancer Test Flow Cytometry , by Region USD Million (2018-2023)
  • Table 15. Cancer Test Other Organ Specific Cancer Test , by Region USD Million (2018-2023)
  • Table 16. South America Cancer Test, by Country USD Million (2018-2023)
  • Table 17. South America Cancer Test, by Type USD Million (2018-2023)
  • Table 18. South America Cancer Test, by Application USD Million (2018-2023)
  • Table 19. Brazil Cancer Test, by Type USD Million (2018-2023)
  • Table 20. Brazil Cancer Test, by Application USD Million (2018-2023)
  • Table 21. Argentina Cancer Test, by Type USD Million (2018-2023)
  • Table 22. Argentina Cancer Test, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Cancer Test, by Type USD Million (2018-2023)
  • Table 24. Rest of South America Cancer Test, by Application USD Million (2018-2023)
  • Table 25. Asia Pacific Cancer Test, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Cancer Test, by Type USD Million (2018-2023)
  • Table 27. Asia Pacific Cancer Test, by Application USD Million (2018-2023)
  • Table 28. China Cancer Test, by Type USD Million (2018-2023)
  • Table 29. China Cancer Test, by Application USD Million (2018-2023)
  • Table 30. Japan Cancer Test, by Type USD Million (2018-2023)
  • Table 31. Japan Cancer Test, by Application USD Million (2018-2023)
  • Table 32. India Cancer Test, by Type USD Million (2018-2023)
  • Table 33. India Cancer Test, by Application USD Million (2018-2023)
  • Table 34. South Korea Cancer Test, by Type USD Million (2018-2023)
  • Table 35. South Korea Cancer Test, by Application USD Million (2018-2023)
  • Table 36. Taiwan Cancer Test, by Type USD Million (2018-2023)
  • Table 37. Taiwan Cancer Test, by Application USD Million (2018-2023)
  • Table 38. Australia Cancer Test, by Type USD Million (2018-2023)
  • Table 39. Australia Cancer Test, by Application USD Million (2018-2023)
  • Table 40. Rest of Asia-Pacific Cancer Test, by Type USD Million (2018-2023)
  • Table 41. Rest of Asia-Pacific Cancer Test, by Application USD Million (2018-2023)
  • Table 42. Europe Cancer Test, by Country USD Million (2018-2023)
  • Table 43. Europe Cancer Test, by Type USD Million (2018-2023)
  • Table 44. Europe Cancer Test, by Application USD Million (2018-2023)
  • Table 45. Germany Cancer Test, by Type USD Million (2018-2023)
  • Table 46. Germany Cancer Test, by Application USD Million (2018-2023)
  • Table 47. France Cancer Test, by Type USD Million (2018-2023)
  • Table 48. France Cancer Test, by Application USD Million (2018-2023)
  • Table 49. Italy Cancer Test, by Type USD Million (2018-2023)
  • Table 50. Italy Cancer Test, by Application USD Million (2018-2023)
  • Table 51. United Kingdom Cancer Test, by Type USD Million (2018-2023)
  • Table 52. United Kingdom Cancer Test, by Application USD Million (2018-2023)
  • Table 53. Netherlands Cancer Test, by Type USD Million (2018-2023)
  • Table 54. Netherlands Cancer Test, by Application USD Million (2018-2023)
  • Table 55. Rest of Europe Cancer Test, by Type USD Million (2018-2023)
  • Table 56. Rest of Europe Cancer Test, by Application USD Million (2018-2023)
  • Table 57. MEA Cancer Test, by Country USD Million (2018-2023)
  • Table 58. MEA Cancer Test, by Type USD Million (2018-2023)
  • Table 59. MEA Cancer Test, by Application USD Million (2018-2023)
  • Table 60. Middle East Cancer Test, by Type USD Million (2018-2023)
  • Table 61. Middle East Cancer Test, by Application USD Million (2018-2023)
  • Table 62. Africa Cancer Test, by Type USD Million (2018-2023)
  • Table 63. Africa Cancer Test, by Application USD Million (2018-2023)
  • Table 64. North America Cancer Test, by Country USD Million (2018-2023)
  • Table 65. North America Cancer Test, by Type USD Million (2018-2023)
  • Table 66. North America Cancer Test, by Application USD Million (2018-2023)
  • Table 67. United States Cancer Test, by Type USD Million (2018-2023)
  • Table 68. United States Cancer Test, by Application USD Million (2018-2023)
  • Table 69. Canada Cancer Test, by Type USD Million (2018-2023)
  • Table 70. Canada Cancer Test, by Application USD Million (2018-2023)
  • Table 71. Mexico Cancer Test, by Type USD Million (2018-2023)
  • Table 72. Mexico Cancer Test, by Application USD Million (2018-2023)
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Cancer Test: by Type(USD Million)
  • Table 83. Cancer Test Laboratory Tests , by Region USD Million (2025-2030)
  • Table 84. Cancer Test Genetic Tests , by Region USD Million (2025-2030)
  • Table 85. Cancer Test Imaging , by Region USD Million (2025-2030)
  • Table 86. Cancer Test Endoscopy , by Region USD Million (2025-2030)
  • Table 87. Cancer Test: by Application(USD Million)
  • Table 88. Cancer Test Bladder Cancer Test , by Region USD Million (2025-2030)
  • Table 89. Cancer Test Breast Cancer Test , by Region USD Million (2025-2030)
  • Table 90. Cancer Test Cervical Cancer Test , by Region USD Million (2025-2030)
  • Table 91. Cancer Test Colorectal (Colon) Cancer Test , by Region USD Million (2025-2030)
  • Table 92. Cancer Test Ovarian Cancer Test , by Region USD Million (2025-2030)
  • Table 93. Cancer Test Prostate Cancer Test , by Region USD Million (2025-2030)
  • Table 94. Cancer Test Liver Cancer Test , by Region USD Million (2025-2030)
  • Table 95. Cancer Test Flow Cytometry , by Region USD Million (2025-2030)
  • Table 96. Cancer Test Other Organ Specific Cancer Test , by Region USD Million (2025-2030)
  • Table 97. South America Cancer Test, by Country USD Million (2025-2030)
  • Table 98. South America Cancer Test, by Type USD Million (2025-2030)
  • Table 99. South America Cancer Test, by Application USD Million (2025-2030)
  • Table 100. Brazil Cancer Test, by Type USD Million (2025-2030)
  • Table 101. Brazil Cancer Test, by Application USD Million (2025-2030)
  • Table 102. Argentina Cancer Test, by Type USD Million (2025-2030)
  • Table 103. Argentina Cancer Test, by Application USD Million (2025-2030)
  • Table 104. Rest of South America Cancer Test, by Type USD Million (2025-2030)
  • Table 105. Rest of South America Cancer Test, by Application USD Million (2025-2030)
  • Table 106. Asia Pacific Cancer Test, by Country USD Million (2025-2030)
  • Table 107. Asia Pacific Cancer Test, by Type USD Million (2025-2030)
  • Table 108. Asia Pacific Cancer Test, by Application USD Million (2025-2030)
  • Table 109. China Cancer Test, by Type USD Million (2025-2030)
  • Table 110. China Cancer Test, by Application USD Million (2025-2030)
  • Table 111. Japan Cancer Test, by Type USD Million (2025-2030)
  • Table 112. Japan Cancer Test, by Application USD Million (2025-2030)
  • Table 113. India Cancer Test, by Type USD Million (2025-2030)
  • Table 114. India Cancer Test, by Application USD Million (2025-2030)
  • Table 115. South Korea Cancer Test, by Type USD Million (2025-2030)
  • Table 116. South Korea Cancer Test, by Application USD Million (2025-2030)
  • Table 117. Taiwan Cancer Test, by Type USD Million (2025-2030)
  • Table 118. Taiwan Cancer Test, by Application USD Million (2025-2030)
  • Table 119. Australia Cancer Test, by Type USD Million (2025-2030)
  • Table 120. Australia Cancer Test, by Application USD Million (2025-2030)
  • Table 121. Rest of Asia-Pacific Cancer Test, by Type USD Million (2025-2030)
  • Table 122. Rest of Asia-Pacific Cancer Test, by Application USD Million (2025-2030)
  • Table 123. Europe Cancer Test, by Country USD Million (2025-2030)
  • Table 124. Europe Cancer Test, by Type USD Million (2025-2030)
  • Table 125. Europe Cancer Test, by Application USD Million (2025-2030)
  • Table 126. Germany Cancer Test, by Type USD Million (2025-2030)
  • Table 127. Germany Cancer Test, by Application USD Million (2025-2030)
  • Table 128. France Cancer Test, by Type USD Million (2025-2030)
  • Table 129. France Cancer Test, by Application USD Million (2025-2030)
  • Table 130. Italy Cancer Test, by Type USD Million (2025-2030)
  • Table 131. Italy Cancer Test, by Application USD Million (2025-2030)
  • Table 132. United Kingdom Cancer Test, by Type USD Million (2025-2030)
  • Table 133. United Kingdom Cancer Test, by Application USD Million (2025-2030)
  • Table 134. Netherlands Cancer Test, by Type USD Million (2025-2030)
  • Table 135. Netherlands Cancer Test, by Application USD Million (2025-2030)
  • Table 136. Rest of Europe Cancer Test, by Type USD Million (2025-2030)
  • Table 137. Rest of Europe Cancer Test, by Application USD Million (2025-2030)
  • Table 138. MEA Cancer Test, by Country USD Million (2025-2030)
  • Table 139. MEA Cancer Test, by Type USD Million (2025-2030)
  • Table 140. MEA Cancer Test, by Application USD Million (2025-2030)
  • Table 141. Middle East Cancer Test, by Type USD Million (2025-2030)
  • Table 142. Middle East Cancer Test, by Application USD Million (2025-2030)
  • Table 143. Africa Cancer Test, by Type USD Million (2025-2030)
  • Table 144. Africa Cancer Test, by Application USD Million (2025-2030)
  • Table 145. North America Cancer Test, by Country USD Million (2025-2030)
  • Table 146. North America Cancer Test, by Type USD Million (2025-2030)
  • Table 147. North America Cancer Test, by Application USD Million (2025-2030)
  • Table 148. United States Cancer Test, by Type USD Million (2025-2030)
  • Table 149. United States Cancer Test, by Application USD Million (2025-2030)
  • Table 150. Canada Cancer Test, by Type USD Million (2025-2030)
  • Table 151. Canada Cancer Test, by Application USD Million (2025-2030)
  • Table 152. Mexico Cancer Test, by Type USD Million (2025-2030)
  • Table 153. Mexico Cancer Test, by Application USD Million (2025-2030)
  • Table 154. Research Programs/Design for This Report
  • Table 155. Key Data Information from Secondary Sources
  • Table 156. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Test: by Type USD Million (2018-2023)
  • Figure 5. Global Cancer Test: by Application USD Million (2018-2023)
  • Figure 6. South America Cancer Test Share (%), by Country
  • Figure 7. Asia Pacific Cancer Test Share (%), by Country
  • Figure 8. Europe Cancer Test Share (%), by Country
  • Figure 9. MEA Cancer Test Share (%), by Country
  • Figure 10. North America Cancer Test Share (%), by Country
  • Figure 11. Global Cancer Test share by Players 2023 (%)
  • Figure 12. Global Cancer Test share by Players (Top 3) 2023(%)
  • Figure 13. Global Cancer Test share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 16. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 17. Radient Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Radient Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 19. BD Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 20. BD Diagnostics (United States) Revenue: by Geography 2023
  • Figure 21. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 22. Beckman Coulter (United States) Revenue: by Geography 2023
  • Figure 23. BioCurex (Mongolia) Revenue, Net Income and Gross profit
  • Figure 24. BioCurex (Mongolia) Revenue: by Geography 2023
  • Figure 25. BioMerieux (France) Revenue, Net Income and Gross profit
  • Figure 26. BioMerieux (France) Revenue: by Geography 2023
  • Figure 27. Cepheid (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cepheid (United States) Revenue: by Geography 2023
  • Figure 29. CytoCore (United States) Revenue, Net Income and Gross profit
  • Figure 30. CytoCore (United States) Revenue: by Geography 2023
  • Figure 31. DiagnoCure (Canada) Revenue, Net Income and Gross profit
  • Figure 32. DiagnoCure (Canada) Revenue: by Geography 2023
  • Figure 33. Global Cancer Test: by Type USD Million (2025-2030)
  • Figure 34. Global Cancer Test: by Application USD Million (2025-2030)
  • Figure 35. South America Cancer Test Share (%), by Country
  • Figure 36. Asia Pacific Cancer Test Share (%), by Country
  • Figure 37. Europe Cancer Test Share (%), by Country
  • Figure 38. MEA Cancer Test Share (%), by Country
  • Figure 39. North America Cancer Test Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Radient Pharmaceuticals (United States)
  • BD Diagnostics (United States)
  • Beckman Coulter (United States)
  • BioCurex (Mongolia)
  • bioMerieux (France)
  • Cepheid (United States)
  • CytoCore (United States)
  • DiagnoCure (Canada)
Additional players considered in the study are as follows:
Hologic (United States) , IIumina Inc. (United States) , Others
Select User Access Type

Key Highlights of Report


Jan 2024 202 Pages 86 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Test Quantitative research analysis
Global Cancer Test Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Radient Pharmaceuticals (United States), BD Diagnostics (United States), Beckman Coulter (United States), BioCurex (Mongolia), bioMerieux (France), Cepheid (United States), CytoCore (United States) and DiagnoCure (Canada) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Cancer Test Market during projected period 2023-2030.
The Cancer Test market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Cancer Test Report?

Have a Query? Click Here

Other Related Reports

Dermatological Therapeutics Comprehensive Study by Type (Anti-infectives , Corticosteroids, Anti Psoriasis, Anti-acne , Others), Application (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopec...
$ 3750
Thyroid Cancer Treatment Comprehensive Study by Type (Surgery, Iodine Therapy, External Radiotherapy, Thyroxin Treatment, Chemotherapy, Drugs), Application (Hospitals, Oncology centers, Hospital Phar...
$ 3650
Urinary Tract Cancer Comprehensive Study by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Others), Diagnosis Technique (Cytoscopy, Urine Analyses, Biopsy, Imaging Test (Compute...
$ 3750
Mesenchymal Stem Cells Comprehensive Study by Type (MSC-BM, MSC-UC, MSC-AT, Others), Application (Cell Differentiation and Gene Regulation, Gene Therapy and Transplantation, Cell-based Screening Assa...
$ 3500
Retinoblastoma Treatment Comprehensive Study by Type (Alkylating Agents, Antimetabolites, Microtubule Inhibitors, Cytotoxic Antibiotics, Topoisomerase Inhibitors), Application (Intraocular Retinoblas...
$ 3750
Orthokeratology Comprehensive Study by Type (Myopia, Hyperopia, Astigmatism, Presbyopia), Application (Ambulatory services, Hospitals, Clinics) Players and Region - Global Market Outlook to 2030
$ 3500